4//SEC Filing
Ildstad Suzanne 4
Accession 0001209191-23-037183
CIK 0001827506other
Filed
Jun 13, 8:00 PM ET
Accepted
Jun 14, 6:58 PM ET
Size
13.9 KB
Accession
0001209191-23-037183
Insider Transaction Report
Form 4
Ildstad Suzanne
DirectorChief Scientific Officer10% Owner
Transactions
- Sale
Common Stock
2023-06-14$2.49/sh−12,942$32,244→ 3,771,392 total - Sale
Common Stock
2023-06-13$2.56/sh−14,208$36,338→ 3,784,334 total - Sale
Common Stock
2023-06-12$2.59/sh−16,870$43,725→ 3,798,542 total - Award
Stock Option (Right to Buy)
2023-06-13+20,500→ 20,500 totalExercise: $2.54Exp: 2033-06-13→ Common Stock (20,500 underlying)
Holdings
- 654,205(indirect: See footnote)
Common Stock
- 654,205(indirect: See footnote)
Common Stock
Footnotes (6)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.52 to $2.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.52 to $2.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.43 to $2.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]These shares are held in a trust for the benefit of the Reporting Person's son. The Reporting Person's son is co-trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- [F5]These shares are held in a trust for the benefit of the Reporting Person's daughter. The Reporting Person's daughter is co-trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- [F6]The shares underlying this option shall vest as follows: the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting.
Documents
Issuer
Talaris Therapeutics, Inc.
CIK 0001827506
Entity typeother
Related Parties
1- filerCIK 0001845822
Filing Metadata
- Form type
- 4
- Filed
- Jun 13, 8:00 PM ET
- Accepted
- Jun 14, 6:58 PM ET
- Size
- 13.9 KB